Stock HROW HARROW, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Harrow, Inc.

Equities

HROW

US4158581094

Market Closed - OTC Markets
Other stock markets
 16:00:00 2024-04-30 EDT 		5-day change 1st Jan Change
10.19 USD -4.05% Intraday chart for Harrow, Inc. -1.26% -9.02%
04-11 Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target MT
03-22 B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Decliners
Harrow, Inc. Provides Earnings Guidance for the Year 2024
Harrow, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Harrow, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Restore stock falls as weak tech trading drags down annual results
Harrow, Inc. Announces Board of Director Appointments
Harrow Health's Eye Treatment Drug Vevye Now Available in US
Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
Harrow, Inc. Partners with Leading Healthcare Market Access Technology Platforms
Harrow Collaborating With Three Health Technology Platforms for US Launch of Vevye
Harrow, Inc. Appoints John P. Saharek as President and Chief Executive Officer of its ImprimisRx Division
Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application
Top Premarket Decliners
Harrow Health Q3 Core Loss Widens, Revenue Rises; Shares Plunge After Hours
Harrow, Inc. Revises Revenue Guidance for the Full Year 2023
Harrow, Inc. Provides Revenue Guidance for the First Quarter and Full Year 2024
Harrow, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Harrow, Inc. Announces Board and Committee Changes
Harrow, Inc. Completes Transfer of Ndas and Launches FLAREX, Natacyn St, Verkazia, and ZERVIATE in the U.S
Insider Buy: Harrow Health
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HROW Stock
  4. News Harrow, Inc.
  5. Other languages